John Babcook is a co-founder and CEO of Evolved Therapeutics. Over the past 35 years he has developed novel antibody generation and antibody-drug conjugate platforms, leading to the establishment of multiple antibody-based companies in Canada. He co-found ImmGenics in 1998, which was acquired by Abgenix in 2000 and by Amgen in 2006, creating Amgen British Columbia. He founded Kairos Therapeutics, focused on ADCs in 2013 and led the merger acquisition with Zymeworks in 2016. He has participated in more than 100 therapeutic antibody-based programs, including several that have been approved by the FDA. John is the recipient of Life Sciences BC’s “Innovation and Achievement and Lifetime Achievement” Awards.
John Babcook
Share: